Truist cuts Inspire Medical Systems stock price target on revenue outlook

Truist Securities reduced its price target for Inspire Medical Systems (NYSE:INSP) to $76 from $78, citing a revised 2028 revenue estimate of $937M. The stock trades at $67.21, considered undervalued. Q3 2026 results beat estimates, with revenue at $206.7M and EPS at $0.14. Wells Fargo raised its target to $69. Growth is expected to re-accelerate to low-single to mid-single digits in 2027-2028.

Original reporting
Published Nov 3, 2026, 11:47 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 12:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$INSP
Bullish
high confidence
Mentioned
$INSP
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$INSPBullishMed
01

Why it matters

Earnings beat and target changes may drive short‑term price appreciation, but long‑term growth could be limited by capacity and competitive pressures.

02

Market read

The fresh earnings data and analyst actions provide a timely trading cue for INSP.

03

What to watch

Potential future reimbursement policy changes and the impact of CPT code adoption timing.

Relevance 6/10Novelty 6/10Timing: after market close

Background

Inspire Medical Systems (INSP) provides spinal cord stimulation devices; its recent earnings beat and analyst target revisions are new information.

Company-level read

Ticker impact

$INSPBullishHigh confidence
Context

Truist lowered its price target to $76 and Wells Fargo raised its target to $69 after Inspire Medical Systems reported Q3 2026 earnings that beat estimates.

Expected impact

likely upward pressure as the market prices in the earnings beat and higher price targets

Evidence & confidence

The beat was driven by better gross margin and lower operating expenses, and two major analysts moved targets higher, indicating fresh positive sentiment.

Market effects

Positive earnings may lift other medtech and device stocks tracking reimbursement trends.

U.S. small‑cap healthcare sector could see modest gains.

Limited to U.S. investors; no broader macro impact.

Counterpoint

The target cuts by Truist suggest lingering concerns over capacity constraints and GLP‑1 competition that could cap growth.

Key entities

  • Truist Securities

    Lowered price target to $76.

  • Wells Fargo

    Raised price target to $69.

Related articles

$INSPMedAI 8/10

Inspire (INSP) Q3 2026 Earnings Call Transcript

Inspire (INSP) reported Q3 2026 revenue of $206.7M, down 7.9% YoY but up 3% sequentially. The company expects stable coding framework in 2027 and a new code in 2028, with strong adoption of Inspire V. Operating loss was $28.7M, and adjusted EPS was $0.14. The company is investing in patient flow optimization and expanding market reach. According to the company, they remain confident in their path to growth.

$INSPMed

Inspire: Q3 Earnings Snapshot

Inspire Medical Systems (INSP) reported a Q3 loss of $24.4M, or 84 cents per share, but adjusted earnings of 14 cents per share, beating estimates. Revenue was $206.7M, also topping forecasts. The company expects full-year earnings of $1.20-$1.40 per share and revenue of $850M-$860M.

$INSPMed

Inspire Medical Systems Q3 Earnings Call Highlights

Inspire Medical Systems (INSP) reported Q3 earnings, estimating coding and reimbursement challenges reduced results by $30M and may impact 2026 results by $120M. The company expects revenue growth in Q4 and low-single-digit growth in 2027, citing stable coding and investments. Inspire highlighted a new CPT code for its Inspire V device and ongoing development of Inspire VI. Management discussed clinical evidence supporting their therapy and plans to invest in patient access and education.

$INSPHighAI 8/10

Inspire Medical Q3 2026 slides: reimbursement clarity ahead, growth reset

Inspire Medical Systems reported Q3 2026 revenue of $206.7M, down 7.9% YoY but up 3.0% sequentially. The company cited reimbursement challenges as the primary headwind. Shares rose 1.83% in after-hours trading. Inspire highlighted its market position and long-term growth potential, despite near-term slowdowns. The company expects full-year 2026 revenue of $850M-$860M, down from 2025 levels.